ADB-CHMINACA
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.
Wikipage redirect
5F-AB-PINACA5F-ADB5F-ADB-PINACA5F-AMB5F-APINACA5F-EMB-PINACAAB-CHFUPYCAAB-CHMINACAAB-FUBINACAAB-PICAAB-PINACAADB-FUBINACAADB-PINACAADBICAAMB-CHMINACAAMB-FUBINACAAPICA (synthetic cannabinoid drug)APINACAAPP-FUBINACAAdamantyl-THPINACAC21H30N4O2Drugs controlled by the German BetäubungsmittelgesetzFUB-APINACAList of Schedule I drugs (US)List of designer drugsList of psychedelic drugsMA-CHMINACAMAB-CHMINACAMDMB-CHMICAMDMB-CHMINACAMDMB-FUBICAMDMB-FUBINACANE-CHMIMOPX-1PX-2PX-3
Link from a Wikipage to another Wikipage
primaryTopic
ADB-CHMINACA
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.
has abstract
ADB-CHMINACA (also known as MA ...... blends in Japan in early 2015.
@en
CAS number
1185887-13-1
FDA UNII code
SL4C60689M
PubChem
Wikipage page ID
46,992,168
page length (characters) of wiki page
Wikipage revision ID
992,845,205
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
48,059,556
IUPAC name
N-[-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-indazole-3-carboxamide
@en
legal CA
Schedule II
@en
legal DE
Anlage II
@en
legal status
Illegal in Singapore, Sweden, Switzerland
@en
legal UK
Class B
@en
legal US
Schedule I
@en
PubChem
68,894,304
SMILES
CC[C@H]C=O
@en
StdInChIKey
ZWCCSIUBHCZKOY-GOSISDBHSA-N
@en
UNII
SL4C60689M
@en
wikiPageUsesTemplate
hypernym
comment
ADB-CHMINACA (also known as MA ...... blends in Japan in early 2015.
@en
label
ADB-CHMINACA
@en